Mannkind Corp (MNKD) Stock Price, Quote & News

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pul...

Industry: Biotechnology

Sector: Healthcare

Phone: 818 661 5000

Website: www.mannkindcorp.com

Address:

1 Casper Street, Danbury, United States

Golf365 Nov. 14 at 9:07 PM

$MNKD Hey @NatesNotes Realistically what price could we be at if all the stars lineup this time next year?

0 · Reply

oloccip__evets Nov. 14 at 8:59 PM

$MNKD Mike, you ready for the weekend ???

0 · Reply

jerchess Nov. 14 at 8:37 PM

$MNKD needs to push through 8 https://www.youtube.com/live/ZGtbbkX_3bw?si=D9wx7fcmUbMNZXve

1 · Reply

Rollertb Nov. 14 at 8:30 PM

$MNKD check it out

0 · Reply

JustAnotherJuggler Nov. 14 at 6:11 PM

$MNKD

1 · Reply

Nakom Nov. 14 at 5:43 PM

$MNKD Something tells me that MNKD 1501 that says Stage Undisclosed is actually the New and Improved Tyvaso DPI utilizing Isperse technology. If I was a betting man they are probably in a phase one right now. Probably will do a bridging study to utilize the new and improved Tyvaso DPI for IPF.

1 · Reply

nomalarkey Nov. 14 at 5:40 PM

$MNKD

0 · Reply

MThunter52 Nov. 14 at 5:24 PM

$MNKD

0 · Reply

nomalarkey Nov. 14 at 5:01 PM

$MNKD

0 · Reply

stevemano Nov. 14 at 4:40 PM

$MNKD added more shares ! Why not.

1 · Reply

MannKind to Present at the Jefferies Global Healthcare Conference

Nov 10, 2025, 1:21 PM EST - 4 days ago

MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript

Nov 10, 2025, 8:00 AM EST - 4 days ago

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

Nov 6, 2025, 9:00 AM EST - 8 days ago

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

Nov 5, 2025, 3:51 PM EST - 9 days ago

MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 8:00 AM EST - 9 days ago

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 4:05 PM EDT - 16 days ago

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

Oct 15, 2025, 12:55 PM EDT - 4 weeks ago

MannKind: Durable Cash Engine, Optional Catalysts Pending

Oct 13, 2025, 8:05 AM EDT - 4 weeks ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

Oct 7, 2025, 9:02 AM EDT - 5 weeks ago

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Sep 29, 2025, 6:05 AM EDT - 6 weeks ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

Sep 16, 2025, 12:17 PM EDT - 2 months ago

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SCPH

Sep 10, 2025, 7:30 PM EDT - 2 months ago

MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 7, 2025, 9:55 PM EDT - 2 months ago

MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:28 PM EDT - 2 months ago

MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 4:05 PM EDT - 2 months ago

MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 8:05 AM EDT - 2 months ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Aug 25, 2025, 1:57 PM EDT - 2 months ago

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

Aug 25, 2025, 1:36 PM EDT - 2 months ago

MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript

Aug 6, 2025, 5:20 PM EDT - 3 months ago

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript

Aug 6, 2025, 4:44 PM EDT - 3 months ago

MannKind Corporation: A Post-Q2 Assessment

Aug 6, 2025, 7:10 AM EDT - 3 months ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:05 AM EDT - 3 months ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Jul 30, 2025, 4:05 PM EDT - 3 months ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jun 11, 2025, 7:01 AM EDT - 5 months ago

Top 3 Health Care Stocks That May Rocket Higher This Quarter

Jun 9, 2025, 4:05 PM EDT - 5 months ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

May 27, 2025, 9:15 AM EDT - 6 months ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025, 12:02 AM EDT - 6 months ago

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition

May 8, 2025, 11:34 AM EDT - 6 months ago

MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:05 AM EDT - 6 months ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 7 months ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Apr 7, 2025, 12:30 PM EDT - 7 months ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Mar 10, 2025, 6:05 AM EDT - 8 months ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Feb 27, 2025, 10:32 AM EST - 9 months ago

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question

Feb 26, 2025, 9:09 PM EST - 9 months ago

MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 9 months ago

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 4:05 PM EST - 9 months ago

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Feb 3, 2025, 9:20 AM EST - 10 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MSTR SKE SKYE AMSC

Jan 6, 2025, 4:30 PM EST - 11 months ago

MannKind Expands Executive Leadership Team

Dec 17, 2024, 7:16 AM EST - 11 months ago

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Dec 16, 2024, 6:05 AM EST - 11 months ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Dec 11, 2024, 6:00 AM EST - 1 year ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

Nov 7, 2024, 8:30 PM EST - 1 year ago

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:02 PM EST - 1 year ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Nov 5, 2024, 4:15 PM EST - 1 year ago

MannKind to Present at 2024 UBS Healthcare Conference

Nov 4, 2024, 6:05 AM EST - 1 year ago

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

Oct 31, 2024, 4:05 PM EDT - 1 year ago

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

Oct 30, 2024, 9:00 PM EDT - 1 year ago

First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Oct 3, 2024, 8:00 AM EDT - 1 year ago

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Sep 30, 2024, 6:00 AM EDT - 1 year ago

More Adults With Type 1 Diabetes Achieved A1C Goal (

Golf365 Nov. 14 at 9:07 PM

$MNKD Hey @NatesNotes Realistically what price could we be at if all the stars lineup this time next year?

0 · Reply

oloccip__evets Nov. 14 at 8:59 PM

$MNKD Mike, you ready for the weekend ???

0 · Reply

jerchess Nov. 14 at 8:37 PM

$MNKD needs to push through 8 https://www.youtube.com/live/ZGtbbkX_3bw?si=D9wx7fcmUbMNZXve

1 · Reply

Rollertb Nov. 14 at 8:30 PM

$MNKD check it out

0 · Reply

JustAnotherJuggler Nov. 14 at 6:11 PM

$MNKD

1 · Reply

Nakom Nov. 14 at 5:43 PM

1 · Reply

nomalarkey Nov. 14 at 5:40 PM

$MNKD

0 · Reply

MThunter52 Nov. 14 at 5:24 PM

$MNKD

0 · Reply

nomalarkey Nov. 14 at 5:01 PM

$MNKD

0 · Reply

stevemano Nov. 14 at 4:40 PM

$MNKD added more shares ! Why not.

1 · Reply

nomalarkey Nov. 14 at 4:03 PM

$MNKD The only thing coming home for Christmas is

0 · Reply

Golf365 Nov. 14 at 3:50 PM

$MNKD

0 · Reply

rooksleanne Nov. 14 at 3:26 PM

$MNKD $PKKFF $SPCE Good Morning 🏃🏼‍♀️☔️

1 · Reply

MayorofMNKD Nov. 14 at 3:23 PM

$MNKD ….OT for those who did not buy OMER it’s not too late all of my humble opinion.

0 · Reply

clan Nov. 14 at 3:20 PM

$MNKD $DXCM $LLY The Nick effect. Is that inhalable insulin he has there?

0 · Reply

Bizconsult Nov. 14 at 2:55 PM

$MNKD I think that things seem to be looking very promising for MNKD. Something seems to be happening now. IMO

3 · Reply

Golf365 Nov. 14 at 2:47 PM

$MNKD Notifications are not working, anybody else having that problem?

1 · Reply

YolitheDolly Nov. 14 at 2:36 PM

$MNKD Any one still think we don’t see the 4’s today. I’m just hoping we close above $5 this year. That would be a real gift. We’d end up at $1 pre RS.

1 · Reply

firefox2778 Nov. 14 at 2:19 PM

$MNKD probably that’s the reason why BP are not selling insulin anymore. Got it

0 · Reply

HumphreyB Nov. 14 at 2:12 PM

$MNKD Get ready for another Xmas massacre

3 · Reply

oloccip__evets Nov. 14 at 2:09 PM

$MNKD #Bump

0 · Reply

oloccip__evets Nov. 14 at 2:08 PM

$MNKD 50K+ people using afrezza after a decade being on the market......

0 · Reply

Market Cap	1.61B
Revenue (ttm)	285.50M
Net Income (ttm)	27.59M
EPS (ttm)	N/A
PE Ratio	52.50
Forward PE	61.05
Profit Margin	9.66%
Debt to Equity Ratio	-4.79

Volume	2,689,701
Avg Vol	4,471,502
Day's Range	N/A - N/A
Shares Out	307.07M
Stochastic %K	9%
Beta	1.11
Analysts	Strong Sell
Price Target	$9.44